Effect of anti-VEGF treatment on nonperfusion areas in ischemic retinopathy
| Autor: | Bin Yan, Ziyi Zhu, Jing Luo, Yongan Meng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
retinal nonperfusion areas
medicine.medical_specialty Retinal Vein business.industry ischemic retinopathy Retinal Diabetic retinopathy Hypoxia (medical) RE1-994 medicine.disease Review And Commentary Vascular endothelial growth factor chemistry.chemical_compound Ophthalmology chemistry Occlusion medicine Ischemic retinopathy anti-vascular endothelial growth factor macular ischemia medicine.symptom business Macular edema |
| Zdroj: | International Journal of Ophthalmology, Vol 14, Iss 11, Pp 1647-1652 (2021) Int J Ophthalmol |
| ISSN: | 2227-4898 2222-3959 |
| Popis: | In recent years, retinal ischemia such as that which occurs in diabetic retinopathy (DR) and retinal vein occlusion (RVO) has become a hotspot of ischemic retinopathy research. High levels of vascular endothelial growth factor (VEGF) are recognized as a major cause of macular edema (ME) in DR and RVO. High concentrations of VEGF in the vitreous can lead to serious retinal ischemia and hypoxia and form retinal nonperfusion areas (NPAs). Different levels of retinal ischemia can represent disease severity and progression. Anti-VEGF therapy as the first-line treatment for ME has been found to be effective in improving vision, but there are still disputes about whether anti-VEGF therapy could improve retinal ischemia and achieve reperfusion of previously developed retinal NPAs. Here, we review and summarize studies of the effects of anti-VEGF drugs on retinal ischemia, especially NPAs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|